Product Description
V-419 is being developed by Sanofi for the treatment of Neisseria Meningitidis, Bacterial Infections, and Virus Diseases. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01553279?term=V-419&draw=2&rank=1)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: MCM Vaccines B.V.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Respiratory Syncytial Virus Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CORAL | P3 |
Recruiting |
Respiratory Syncytial Virus Infections |
2025-09-30 |